NKGen Biotech, Inc.
NKGN
$0.1381
$0.00261.92%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.84% | 70.61% | 37.07% | 147.50% | 58.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.67% | 12.80% | 12.11% | 50.67% | 15.15% |
| Operating Income | 1.67% | -12.80% | -12.11% | -50.67% | -15.20% |
| Income Before Tax | 119.89% | -104.97% | 35.33% | -384.07% | -395.70% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | 119.89% | -104.97% | 35.33% | -383.68% | -395.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.89% | -104.97% | 35.33% | -383.68% | -395.70% |
| EBIT | 1.67% | -12.80% | -12.11% | -50.67% | -15.20% |
| EBITDA | 1.70% | -13.48% | -12.81% | -53.38% | -15.92% |
| EPS Basic | 109.15% | -12.95% | 60.74% | -68.14% | -125.28% |
| Normalized Basic EPS | 85.08% | -122.19% | 64.24% | -70.47% | -116.87% |
| EPS Diluted | 106.16% | -12.95% | 60.74% | -68.14% | -125.28% |
| Normalized Diluted EPS | 89.48% | -122.19% | 64.24% | -70.47% | -116.87% |
| Average Basic Shares Outstanding | 117.44% | 81.50% | 64.77% | 187.65% | 120.05% |
| Average Diluted Shares Outstanding | 208.49% | 81.50% | 64.77% | 187.65% | 120.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |